Big Pharma, ready to sail the ocean of B
Market share grows nearly double in 10 years
Invest to prepare for market expansion in real
It is predicted that biomedicines will replace the 70 percent of chemical drugs in the medicine market in 20 years. This triggered Big Pharmas to invest on the production base as a strategy to cope with enlightenment of market.
According to the report of IMS, it is estimated that growth of sales of medicines will hit 8 percent in 2014 and growth of it will decrease little by little and then, it will stay in average range of 3 to 6 percent.
However, that is not the story of biomedicine.
Chemical drugs such as medicines for hypertension and hyperlipidemia, and asthma were leading the medicine market in the world until now. However, in aspect of growth, biomedicine is passing the chemical drugs by far.
In reality, the biomedicine market share was only 13 percent in 2004, and it grew to 21 percent in 2014. In 2008, global price ranking top 10 had only 3 of biomedicines, and it is 5 now.
Due to the atmosphere, global big pharmas are in process of coping with this trend. They expand their production bases, and establish new ones, which shows that they are focusing on the new market coming.
First of all, Pfizer.Inc announced their plan to establish a new plant in Hangzhou, China. They invested 350 million dollars only in this project, which will have facilities for production of biosimilar. If this is completed, it will be the first plant of them in Asia.
The scale of Chinese market and improvement of environment regulation seemed to contribute to this. Currently, Chinese government is seeking ways to minimize the confirming process of sales permission subject to foreign pharmaceutical companies, and permitting production of biosimilar while they reform the health services.
Sanofi also decided to expand their biomedicine production line. This company took over Genzyme with 20.1 billion dollars to reinforcing their biomedicine department, which will be significant move to enter the rare medicine market. Then, they decided to invest 0.3 billion Euro to expand their biomedicine plant in Belgium. Their stragegy is to promote diversity in fields such as cardiovascular diseases, rheumatoid arthritis, and atopic dermatitis, and producing monoclonal antibody, while they secure additional 8000m2 to increase the amount of production. Among pipelines Sanofi owns, 70 percent was dedicated for biomedicines, and 40 percent of these are occupied by monoclonal drugs.
Boehringer ingelheim decided to invest about 0.5 billion Euro on biomedicine production facilities. This decision is caused by high demand on producing biomedicines, and they are trying to secure additional market supply by independent production base. New invest on this company will be held at Wien Austria, where their facilities are located, and planned to be start operating from 2021. Production of Pharmaceutical ingredients in Wien will be transfered to new facilities in the future.
Novonordisk from Denmark is undergoing the expansion of biggest insuline production line in the world. It is less then a year from last year when the company announced to invest about 2 billion dollars to expand bio medicine production facilities. It seemed that strategy to cope with demand of insuline, which is increased drastically in recent years is a huge cuase for this plan. The plant will be completed by year of 2018. Currently, 50 percent of total insuline in the world is produced here along with medicines for diabetes and hemophilia.
Samsung added Korean trend of biomedicine.
Samsung Biologics invested 850 billion Korean Won to construct the production base number 3 in Song-do, Korea, which is capable of producing 180,000 liters per year, which is their strategy to rise drastically in the global biomedicine market. The company announced their plan to become number 1 CMO in the world by securing 360,000 liter production facilities.